Q-omics provides the consensus-scored STK31 profile across patient tissues and cancer cell-line models. STK31 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STK31 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, STK31 RNA expression shows 14,698 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where STK31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK31 survival associations across molecular data types. STK31 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK31 RNA expression–survival associations across cancer types. High STK31 expression shows unfavorable associations in KIRC, KICH, LGG, THCA, PAAD and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STK31 RNA expression.
This table summarizes STK31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK31 shows higher tumor expression in COAD, HNSC, BLCA, LUAD, STAD and READ. The COAD box plot shows higher STK31 RNA expression in tumor versus normal tissue (log2 FC = +1.294, t-test p < 0.001).
This table shows molecular features associated with STK31 in patient tissues and cancer cell lines. In patient samples, STK31 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STK31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
